MICHELLE VASQUEZ: Open Payments
NPI 1952613085 · VALPARAISO, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$693 in 31 payments from 15 companies in 2025. Trend: 2023 $404 · 2024 $748 · 2025 $693
Food & beverage: $693
| Company | Payments | Amount |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 5 | $149 |
| ABBVIE INC. | 6 | $145 |
| Ardelyx, Inc. | 4 | $90 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $73 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Merck Sharp & Dohme LLC | 2 | $32 |
| EMD Serono, Inc. | 1 | $30 |
| Novo Nordisk Inc | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
Products named: NUZYRA, IBSRELA, XIFAXAN, VRAYLAR, FANAPT, GARDASIL 9, DALVANCE, TEFLARO.
Industry payments across IN — which companies pay providers there.
